CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.49
-1.05 (-1.32%)
As of 3:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close79.54
Open79.41
Bid78.50 x 1100
Ask78.51 x 800
Day's Range78.34 - 79.52
52 Week Range74.13 - 147.17
Volume3,826,097
Avg. Volume7,506,571
Market Cap57.01B
Beta1.31
PE Ratio (TTM)21.56
EPS (TTM)3.64
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est115.73
Trade prices are not sourced from all markets
  • Celgene Hammered, Again, On 'Subpar' Success In Developing Drugs
    Investor's Business Daily53 minutes ago

    Celgene Hammered, Again, On 'Subpar' Success In Developing Drugs

    Celgene took another sell-side beating Friday after investment bank Leerink suggested its rate of drug-development success lags the industry average for biotech companies.

  • ACCESSWIRE4 hours ago

    DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $500K of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Celgene Corporation ("Celgene" or the "Company") (CELG) and certain of its officers, on behalf of shareholders who purchased Celgene securities between January 12, 2015 and February 27, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

  • How Ionis’s Spinraza Did in Q1
    Market Realist6 hours ago

    How Ionis’s Spinraza Did in Q1

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

  • The Wall Street Journal15 hours ago

    [$$] Celgene’s Buybacks Are Coming Up Empty

    Celgene is opening its wallet yet again, but to what end? The struggling biotech giant announced Thursday that it plans to spend $2 billion on an accelerated stock repurchase. Celgene’s shares rose early Thursday as they typically do after such announcements, but the pace of Celgene’s buybacks shouldn’t do much to reassure investors.

  • GlobeNewswire19 hours ago

    $100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG)

    Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Celgene Corporation (“Celgene” or the “Company”) (CELG) between September 12, 2016 and February 27, 2018, inclusive (the “Class Period”). Celgene investors have until May 29, 2018 to file a lead plaintiff motion. To obtain information or actively participate in the class action, please visit Celgene page on our website at www.glancylaw.com/case/celgene-corporation.

  • What Drove Ionis’s Revenue in Q1
    Market Realist21 hours ago

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.

  • Agios (AGIO) Progressing Well on Pipeline Amid Competition
    Zacks23 hours ago

    Agios (AGIO) Progressing Well on Pipeline Amid Competition

    Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.

  • Moody'syesterday

    Celgene Corporation -- Moody's: Celgene's accelerated share repurchase credit negative

    Moody's Investors Service commented that the $2 billion accelerated share repurchase program announced by Celgene Corporation ("Celgene") is credit negative. There is no impact on the company's ratings including the Baa2 senior unsecured long-term rating and the Prime-2 commercial paper rating or stable rating outlook. For additional information please refere to Moody's issuer comment on Celgene available on www.moodys.com.

  • ETF Trendsyesterday

    Will “Right to Try” Bill Boost Biotech ETFs?

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.

  • Oil Drags On Opening Trade; Dow Lags, Celgene Surges
    Investor's Business Dailyyesterday

    Oil Drags On Opening Trade; Dow Lags, Celgene Surges

    Celgene and General Electric were leaders in Thursday's mixed open, as investors sorted news of new tariffs, and a third straight drop in oil prices.

  • TheStreet.comyesterday

    Celgene Shares Rise on Plans to Increase Stock Buybacks

    rose in premarket trading on Thursday, May 24, after the biotech firm said its board had authorized an additional $3 billion of stock buybacks. The Summit, N.J.-based company also said it plans to enter into an accelerated share repurchase agreement (ASR) to buy back $2 billion of stock. "The increase in our share repurchase authorization and planned accelerated share repurchase program reflects our confidence in the long-term potential of Celgene," said Celgene chairman and CEO Mark J. Alles in a statement.

  • I Just Bought My First New Stock in 8 Months, and This Is It
    Motley Foolyesterday

    I Just Bought My First New Stock in 8 Months, and This Is It

    This biotech blue chip is simply too enticing to pass up.

  • MarketWatchyesterday

    Celgene shares jump 1.2% premarket on news of additional $3 billion share buyback

    Celgene Corp. shares jumped 1.2% in premarket trade Thursday, after the company announced an additional $3 billion share buyback authorization. The biotech company said it will execute a $2 billion accelerated ...

  • Business Wireyesterday

    Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program

    Celgene Corporation (CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock. In addition, the Company plans to enter into an accelerated share repurchase (ASR) agreement to repurchase an aggregate of $2 billion of the Company’s common stock. The planned ASR will utilize part of the existing Board authorized share repurchase program as well as part of the new authorization.

  • Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
    Motley Foolyesterday

    Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio

    Which stock wins in a head-to-head match-up between these two clinical-stage biotechs?

  • Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges
    Investor's Business Daily2 days ago

    Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges

    Wall Street was split Wednesday on Celgene as one sell-side analyst downgraded the stock saying it "has tilted to greater risk" while another upgraded shares.

  • GlobeNewswire2 days ago

    CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018

    NEW YORK, May 23, 2018-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors ...

  • Motley Fool2 days ago

    David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off?

    It's been two years since David's picked a batch of stocks made to thrive in a global society that's ever more focused on the life of the mind.

  • Benzinga2 days ago

    Celgene Wins One Bull, Loses Another On Revlimid Potential

    Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102. By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.

  • Celgene Cratering to Four-Year Low Leaves Analysts Split
    Bloomberg2 days ago

    Celgene Cratering to Four-Year Low Leaves Analysts Split

    Celgene Corp. sell-side analysts can’t agree on what’s next for the company with shares hovering near a four-year low. Argus analyst David Toung moved to the sidelines on a risk-reward that has “tilted to greater risk” given an over-reliance on one of the world’s biggest brand-name cancer treatments, Revlimid. Shares tumbled on Monday to a four-year low after a news article about the departure of its former business development head, George Golumbeski, added gasoline to the fire of concerns for the drugmaker.

  • Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It
    Motley Fool2 days ago

    Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It

    The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.

  • Business Wire3 days ago

    The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG)

    Law Offices of Howard G. Smith reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Celgene Corporation (“Celgene” or the “Company”) (NASDAQ: CELG) securities between January 12, 2015 and February 27, 2018, inclusive (the “Class Period”). Celgene investors have until May 29, 2018 to file a lead plaintiff motion.

  • GlobeNewswire3 days ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The Firm

    Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celgene Corporation (“Celgene” or the “Company”) (CELG) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Celgene stock or options between September 12, 2016 and February 27, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/CELG.  There is no cost or obligation to you.

  • Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
    Investor's Business Daily3 days ago

    Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene

    Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.

  • Celgene Corporation: How to Effectively Buy Into CELG Stock
    InvestorPlace3 days ago

    Celgene Corporation: How to Effectively Buy Into CELG Stock

    After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. In fact and with shares of Celgene now off a full 50% from 2017’s all-time-highs following Monday’s 4.70% price drop, you could say bears have been acting with barely any hesitation in CELG stock. The latest ‘disappointment’ in shares of Celgene, judging by Monday’s price reaction, is a report that Celgene’s top dog of business development discreetly retired over a month ago.